alendronate sodium

DRUG14 trials

Sponsors

Children's Hospital Medical Center, Cincinnati, University of North Carolina, National Cancer Institute (NCI), Eli Lilly and Company, Barwon Health

Conditions

Adenocarcinoma of the ProstateAvascular NecrosisBeta Blocker ToxicityBone MetastasesBreast CancerCystic FibrosisGaucher's DiseaseGlucocorticoid Induced Osteoporosis

Phase 2

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

CompletedNCT00004488

Children's Hospital Medical Center, CincinnatiGaucher's Disease, Osteopenia

Start: 1998-10-31End: 2002-09-30Target: 82Updated: 2015-03-25

Network Osteoporosis Study

Glaser Pediatric Research NetworkOsteopenia, Osteoporosis

Start: 2002-07-31End: 2007-02-28Target: 90Updated: 2005-09-21

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

TerminatedNCT00019695

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Bone Metastases, Recurrent Prostate Cancer +1

Start: 1999-03-31End: 2005-03-31Updated: 2024-03-04

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

CompletedNCT00996801

Merck Sharp & Dohme LLCOsteoporosis, Postmenopausal Osteoporosis

Start: 2009-11-30End: 2011-06-30Updated: 2016-01-22

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Shanghai JMT-Bio Inc.Glucocorticoid Induced Osteoporosis

Start: 2022-06-15End: 2023-06-01Target: 231Updated: 2022-05-31

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

RecruitingNCT06016634

University of California, DavisAvascular Necrosis, Ischemic Necrosis, Osteonecrosis +2

Start: 2026-02-09End: 2027-12-31Target: 30Updated: 2026-01-30

Phase 3

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

CompletedNCT00051558

Eli Lilly and CompanyOsteoporosis

Start: 2002-11-30End: 2008-01-31Updated: 2009-03-12

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

CompletedNCT00122356

Barwon HealthBreast Cancer

Start: 2005-09-30End: 2013-03-31Updated: 2013-03-13

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

CompletedNCT00354302

NCIC Clinical Trials GroupBreast Cancer, Osteoporosis

Start: 2006-04-24End: 2012-01-06Updated: 2020-04-02

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

RecruitingNCT04704947

Sherief Abd-ElsalamBeta Blocker Toxicity

Start: 2017-10-01End: 2030-10-01Target: 50Updated: 2021-01-12

Phase 4

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

CompletedNCT00504166

University of California, San FranciscoOsteopenia, Osteoporosis

Start: 2006-02-28End: 2009-04-30Updated: 2013-08-14

Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.

CompletedNCT02795546

Panineeya Mahavidyalaya Institute of Dental Sciences & Research CentreIntrabony Periodontal Defect

Start: 2015-01-31End: 2016-04-30Updated: 2016-06-10

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Active, not recruitingNCT05493761

Aristotle University Of ThessalonikiNonalcoholic Fatty Liver, Osteoporosis, Postmenopausal

Start: 2022-12-23End: 2026-09-30Updated: 2025-07-18

Unknown Phase

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

CompletedNCT00004489

University of North CarolinaCystic Fibrosis, Osteoporosis

Start: 1998-10-31End: 2002-09-30Target: 60Updated: 2015-03-25

Related Papers

Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.

2021-02-193 citations

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

2014-03-1138 citations

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.

2009-11-1646 citations

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

2007-11-01542 citations